Adam Fine

ChromaCode is a molecular diagnostics company with a bioinformatics focus and pedigree from Illumina, Google[x], Luminex, and Caltech. We leverage patented mathematical methods and algorithmic enhancements to enrich signal processing from the most popular life science instrumentation. We are using this to extract new information on biochemistry reactions and substantially increase the performance capabilities of today’s gold-standard biochemical assays at a very low cost. Visit us at www.chromacode.com.

Upward Health is a risk-bearing multi-specialty provider that partners with health plans and other risk-bearing entities to address the unique needs of the most high-risk, high-need users of the health care system today. Using a unique, holistic, community-based approach to meeting a plan member’s needs, Upward Health facilitates and delivers care that improves outcomes and the quality of life for every member they serve. For more information, visit: upwardhealth.com.

Andros is a health technology company that solves the multiple challenges healthcare organizations experience building, managing, and optimizing provider networks. Built on the industry’s largest provider data resource, the Andros software suite leverages data intelligence and automated workflows to recruit, contract, credential, and monitor healthcare providers and networks nationwide. Innovative health plans, governmental entities, and telehealth companies deliver healthcare to counties containing over 90% of the United States’ population through networks built and managed with Andros technology.

Neuspera Medical, Inc. is committed to developing implantable medical device technology that will improve the lives of patients battling chronic illness. With the first intended indication for use as Urinary Urgency Incontinence (UUI), the platform technology is ultimately designed to deliver targeted bioelectronic medicine for a variety of conditions. Neuspera’s minimally-invasive implants with external wearable transmitters offer the possibility for therapies to reach deeper, harder to access anatomical locations in the body.

Personal Genome Diagnostics (PGDx) is empowering the fight against cancer by unlocking actionable information from the genome. We are committed to developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide. Our expertise in advanced cancer genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing, proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive approaches in cancer. PGDx was founded in 2010 by Luis Diaz and Victor Velculescu to help bring novel diagnostic approaches to patients with cancer. They are internationally recognized leaders in cancer genomics who have extensive experience in the application of innovative genomic technologies for drug development and clinical practice. Named a 2019 Top Workplace by The Baltimore Sun Named a 2018 winner of the Best Place to Work by the Business Intelligence Group

Cureatr is the new breed of clinical provider. We use cutting-edge healthcare data, technology, insights, and patient relationship-building to solve the complex medication management equation.

Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder. Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates.

Nuvaira, Inc. develops innovative and groundbreaking therapies that aim to improve the lives of the more than 65 million people around the world with obstructive lung disease. Founded in 2008, Nuvaira was established to address clinical needs in the treatment of overactive airway nerves, a common disease feature of both COPD and asthma. Nuvaira is a privately held medical device company, headquartered in Minneapolis, Minnesota USA and has more than 75 patents issued and pending worldwide. The dNerva® Lung Denervation System is CE Mark approved. The dNerva® lung denervation system is under clinical investigation and is not commercially available in the USA.

ChromaCode is a molecular diagnostics company with a bioinformatics focus and pedigree from Illumina, Google[x], Luminex, and Caltech. We leverage patented mathematical methods and algorithmic enhancements to enrich signal processing from the most popular life science instrumentation. We are using this to extract new information on biochemistry reactions and substantially increase the performance capabilities of today’s gold-standard biochemical assays at a very low cost. Visit us at www.chromacode.com.

Upward Health is a risk-bearing multi-specialty provider that partners with health plans and other risk-bearing entities to address the unique needs of the most high-risk, high-need users of the health care system today. Using a unique, holistic, community-based approach to meeting a plan member’s needs, Upward Health facilitates and delivers care that improves outcomes and the quality of life for every member they serve. For more information, visit: upwardhealth.com.

Andros is a health technology company that solves the multiple challenges healthcare organizations experience building, managing, and optimizing provider networks. Built on the industry’s largest provider data resource, the Andros software suite leverages data intelligence and automated workflows to recruit, contract, credential, and monitor healthcare providers and networks nationwide. Innovative health plans, governmental entities, and telehealth companies deliver healthcare to counties containing over 90% of the United States’ population through networks built and managed with Andros technology.

Neuspera Medical, Inc. is committed to developing implantable medical device technology that will improve the lives of patients battling chronic illness. With the first intended indication for use as Urinary Urgency Incontinence (UUI), the platform technology is ultimately designed to deliver targeted bioelectronic medicine for a variety of conditions. Neuspera’s minimally-invasive implants with external wearable transmitters offer the possibility for therapies to reach deeper, harder to access anatomical locations in the body.

Personal Genome Diagnostics (PGDx) is empowering the fight against cancer by unlocking actionable information from the genome. We are committed to developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide. Our expertise in advanced cancer genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing, proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive approaches in cancer. PGDx was founded in 2010 by Luis Diaz and Victor Velculescu to help bring novel diagnostic approaches to patients with cancer. They are internationally recognized leaders in cancer genomics who have extensive experience in the application of innovative genomic technologies for drug development and clinical practice. Named a 2019 Top Workplace by The Baltimore Sun Named a 2018 winner of the Best Place to Work by the Business Intelligence Group